Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03916185 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT03916185 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 67 participants.
The verdict
NCT03916185, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSV ΔNS2/Δ1313/I1314L Vaccine
- BIOLOGICAL RSV 6120/ΔNS2/1030s Vaccine
- BIOLOGICAL RSV 276 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03916185
The ClinicalTrials.gov registry entry for NCT03916185 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03916185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03916185 about?
NCT03916185 is a clinical study titled "Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age". The purpose of this study was to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.
What is the current status of trial NCT03916185?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2019-06-20. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT03916185?
The interventions under investigation include: Placebo (BIOLOGICAL), RSV ΔNS2/Δ1313/I1314L Vaccine (BIOLOGICAL), RSV 6120/ΔNS2/1030s Vaccine (BIOLOGICAL), RSV 276 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03916185?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.